OnCo
pairingsPairing

Chemo-immunotherapy induction → maintenance intensification (SCLC)

Chemo-immunotherapy followed by maintenance in small-cell lung cancer gives four cycles of chemotherapy plus immunotherapy, then keeps the immunotherapy going and adds a second drug to hold the disease longer.

IMforte showed adding lurbinectedin to atezolizumab maintenance improves OS; DeLLphi-305 tests tarlatamab in the same slot. Maintenance intensification is the first new first-line strategy since chemo-immunotherapy itself.

Platinum + etoposide (EP / CE)→ thenLurbinectedinsequence
Rationale
Extensive-stage SCLC almost always relapses within months of induction; targeting residual disease during the response window with a non-cross-resistant agent delays relapse.
Evidence
Phase 3 IMforte positive (2025, FDA approved); DeLLphi-305 pending.

Connected

7top

Pages like this

not linked directly; found by shared links

cancers

1
Small-cell lung cancer

drugs

4
ApprovedMonoclonal antibody (anti-PD-L1)
Atezolizumab · Tecentriq / Tecentriq Hybreza (SC)
ApprovedCytotoxic (transcription inhibitor)
Lurbinectedin · Zepzelca
Not mapped hereCytotoxic regimen
Platinum + etoposide (EP / CE)
ApprovedBispecific T-cell engager (DLL3×CD3)
Tarlatamab · Imdelltra

trials

2
DeLLphi-305IMforte